Latest news with #AardvarkTherapeutics
Globe and Mail
2 days ago
- Business
- Globe and Mail
Trending Stocks By Analyst's for this Week
Analyst Ratings (USA) Aardvark Therapeutics was rated Buy by HC Wainwright, with a target price of $40.00. AbbVie received a Buy rating from Morgan Stanley, with a price target of $250.00. Aemetis had its target raised by UBS Group, reaffirming a Buy rating and lifting the price from $2.20 to $3.00. AeroVironment was initiated with a Buy rating by The Goldman Sachs Group, targeting $301.00. Affirm had its target raised by Barclays and maintained an Overweight rating, with the price increased from $67.00 to $80.00. Agnico Eagle Mines received an Outperform initiation from Raymond James Financial, with a target price of $130.00. Agree Realty was reiterated as Market Perform by JMP Securities. Air Products and Chemicals was reiterated with a Buy rating by Citigroup, increasing the target from $310.00 to $320.00. Alnylam Pharmaceuticals had its target raised by Wells Fargo & Company, maintaining an Equal Weight rating, and the price increased from $287.00 to $333.00. American Healthcare REIT was initiated at Sector Outperform by Scotiabank, with a target of $42.00. Amgen received a Buy rating from TD Cowen, with a price target of $389.00. Amgen was rated Hold by Morgan Stanley, with a target of $330.00. Amplify Energy was initiated with a Buy rating by Alliance Global Partners, with a price target of $6.00. Anglogold Ashanti PLC received a Buy rating from Roth MKM, with a target price of $54.00. Antero Resources was rated Hold by Citi, with a target of $45.00. Aramark was maintained at Equal Weight by Morgan Stanley, with a price target increase from $42.00 to $44.00. Argenx Se also received a Buy rating from Wells Fargo, targeting $741.00. Argenx Se was rated Buy by Citi, with a target price of $803.00. ARM had its target raised by Guggenheim, keeping a Buy rating and lifting the price from $147.00 to $187.00. Aurinia Pharmaceuticals was rated Buy by both Leerink Partners and TD Cowen, with targets of $10.00 and $11.00, respectively. Aytu BioPharma was given a Buy initiation by Ascendiant Capital Markets, with a target price of $12.00. B2Gold was initiated with an Outperform rating by Raymond James Financial, targeting $4.50. Baker Hughes Company was rated Buy by Wells Fargo, aiming for $50.00. Beazer Homes USA was initiated as Neutral by B. Riley, with a target of $23.00. BioCryst Pharmaceuticals had its Outperform rating reiterated by Royal Bank of Canada, with a target of $13.00. BioCryst received a Buy rating from BofA Securities, with a target of $15.00. Boeing was rated Buy by Citi, with a price target of $220.00. Boyd Gaming had its Outperform rating reaffirmed by Raymond James Financial, and its target raised from $81.00 to $85.00. BridgeBio Pharma had its target raised by Wells Fargo & Company, keeping an Overweight rating and raising the price from $67.00 to $76.00. BridgeBio Pharma received a Buy rating from Raymond James, with a price target of $57.00. Brookfield Asset Management was initiated with a Neutral rating by Piper Sandler, targeting $60.00. CAE was initiated with a Buy rating by The Goldman Sachs Group, with a target of $33.00. Candel Therapeutics received a Buy initiation from HC Wainwright, targeting $23.00. Capricor Therapeutics was initiated at Buy by Alliance Global Partners, with a price target of $20.00. CarMax received a Buy rating from Morgan Stanley, with a price target of $80.00. Celcuity had its Buy rating reiterated by Needham & Company LLC, with a target of $29.00. Celcuity received a Buy rating from LifeSci Capital, with a target of $27.00. Cencora was rated Hold by Jefferies Financial Group, with a raised target of $300.00. Century Communities was initiated with a Buy rating by B. Riley, targeting $70.00. Chemed had its Buy rating maintained by Bank of America, though the price target was lowered from $708.00 to $650.00. Cidara Therapeutics had its Market Outperform rating reiterated by JMP Securities, with a target of $59.00. Circle Internet Group was rated Buy by Canaccord Genuity Group, with a target price of $247.00. Circle Internet Group was rated Buy by Citigroup, with a target price of $243.00. Circle Internet Group was rated Buy by Needham & Company LLC, with a target price of $250.00. Circle Internet Group was rated Hold by Deutsche Bank Aktiengesellschaft, with a target price of $155.00. Circle Internet Group was rated Market Perform by Oppenheimer (no price target provided). Circle Internet Group was rated Neutral by The Goldman Sachs Group, with a target price of $83.00. Circle Internet Group was rated Outperform by Sanford C. Bernstein, with a target price of $230.00. Circle Internet Group was rated Overweight by Barclays, with a target price of $215.00. Circle Internet Group was rated Underweight by JPMorgan Chase & Co., with a target price of $80.00. Citius Pharmaceuticals was rated Buy by D. Boral Capital, with a target of $6.00. Clene was rated Buy by D. Boral Capital, with a target price of $23.00. Cloudastructure received a Buy rating from Maxim Group, targeting $6.00. Coeur Mining was rated Buy by Roth MKM, with a target price of $12.00. Cogent Biosciences was rated Neutral by Wedbush, targeting $10.00. Cohen & Steers was initiated with an Underperform rating by Bank of America, targeting $67.00. Comfort Systems USA was rated Buy by DA Davidson, and the price target was raised to $630.00. Concentrix was rated Buy by Canaccord Genuity Group, with a price target of $80.00. Consolidated Edison was upgraded to Outperform by Mizuho, with a target of $107.00. CoreCivic received a Buy rating from Texas Capital Securities, targeting $28.00. CorMedix was downgraded to Hold by D. Boral Capital (no new price target provided). Crocs was rated Buy by Bank of America, with a reduced target of $135.00. CVS Health was rated Buy by Jefferies Financial Group, with a new target of $80.00. Dave was rated Buy by Benchmark, with a raised price target of $320.00. Dayforce was rated Buy by Needham & Company LLC, targeting $95.00. Delek US was rated Outperform by Raymond James Financial, with a price target of $23.00. Dianthus Therapeutics was assigned a Buy rating by LifeSci Capital, with a target of $45.00. DoorDash was rated Outperform by Oppenheimer, targeting $280.00. Driven Brands was initiated as Buy by BTIG Research, targeting $22.00. Duolingo was rated Buy by Evercore ISI, targeting $540.00. Dutch Bros was initiated as Outperform by CICC Research, targeting $80.00. eBay was rated Equal Weight by Wells Fargo & Company, with a new target of $66.00. Edgewise Therapeutics was initiated with a Buy rating by HC Wainwright, with a price target of $42.00. Emerson Electric Company received a Buy rating from KeyBanc, with a price target of $155.00. Etsy was rated Underweight by Wells Fargo & Company, with a raised target of $41.00. Exelixis was rated Buy by HC Wainwright, with a revised target of $53.00. Expand Energy also received a Buy rating from Mizuho Securities, with a target of $142.00. Expand Energy received a Buy rating from Citi, targeting $140.00. Expeditors International of Washington was rated Hold by Truist Financial, with a revised target of $110.00. Expro Group Holdings received a Buy rating from Wells Fargo, with a target price of $12.00. Fabrinet was rated Buy by Fox Advisors, with a target of $335.00. Federal Signal was rated Outperform by Raymond James Financial, with a raised target of $120.00. First Busey was initiated as Market Perform by Hovde Group, with a target of $25.00. First Solar received a Buy rating from Wells Fargo, with a price target of $177.00. Frequency Electronics received a Buy rating from Freedom Capital Markets, targeting $27.00. Fulcrum Therapeutics was rated Sell by BofA Securities, with a price target of $6.00. Gain Therapeutics received a Buy rating from BTIG, with a price target of $10.00. Gain Therapeutics was rated Buy by Roth MKM, with a target price of $7.00. GeneDx was rated Buy by Guggenheim, with an increased target of $115.00. Genius Sports was rated Market Outperform by JMP Securities, with a raised price target of $13.00. Genpact received a Buy rating from Needham & Company LLC, targeting $50.00. Geo Group was also rated Buy by Texas Capital Securities, with a target of $30.00. Green Brick Partners was initiated with a Neutral rating by B. Riley, with a target of $62.00. Grindr received a Market Outperform rating from JMP Securities, with a raised target of $27.00. Guaranty Bancshares was rated Overweight by Stephens, targeting $47.00. GXO Logistics was rated Hold by Truist Financial, with a revised target of $48.00. Hewlett Packard Enterprise received a Buy rating from Bank of America, with a raised target of $23.00. Hippo Holdings was rated Buy by Financial, with a price target of $35.00. Home Depot received a Buy rating from Citi, aiming for $433.00. Home Depot received a Buy rating from Wells Fargo, with a price target of $420.00. Home Depot was rated Outperform by Telsey Advisory Group, targeting $455.00. Howmet Aerospace was rated Outperform by Royal Bank Of Canada. Hyatt Hotels also received a Buy rating from BofA Securities, targeting $150.00. Hyatt Hotels received a Hold rating from Morgan Stanley, targeting $132.00. Hyatt Hotels was rated Buy by Bernstein, targeting $167.00. Iamgold was initiated with a Market Perform rating by Raymond James Financial, targeting $8.00. Indivior was rated Buy by Craig Hallum, with a raised target of $22.00. Inmune Bio was rated Hold by BTIG, with a price target of $21.00. Inuvo received a Buy rating from HC Wainwright, with a target raised to $15.00. Ionis Pharmaceuticals was rated Buy by Barclays, targeting $57.00. It also received a target raise from Wedbush, maintaining the Outperform rating and increasing the price from $16.00 to $18.00. J.B. Hunt Transport Services was rated Hold by Truist Financial, with a new price target of $140.00. Joby Aviation was rated Buy by Canaccord Genuity, with a target of $12.00. KB Home received a Sell rating from CFRA, with a price target of $49.00. Kellanova received a Hold rating from TD Cowen, with a price target of $83.50. Kinross Gold was initiated with a Market Perform rating by Raymond James Financial, targeting $15.00. KKR & Co. Inc. was initiated with an Overweight rating by Piper Sandler, targeting $150.00. Kratos Defense & Security Solutions was upgraded to Buy by The Goldman Sachs Group, targeting $52.00. Krystal Biotech was rated Buy by Clear Street, with a target of $190.00. Largo received a Buy rating from HC Wainwright, targeting $3.70. Lear was rated Buy by Citigroup, with a raised target of $136.00. Leonardo DRS was initiated as Buy by The Goldman Sachs Group, with a target of $49.00. Linde was upgraded to Buy by Citigroup, with a raised target of $535.00. M&T Bank was assigned a Buy rating by RBC Capital, with a target of $200.00. Marathon Petroleum was rated Strong-Buy by Raymond James Financial, with a raised target of $188.00. MasTec was rated Buy by Roth MKM, with a target of $210.00. McDonald's was rated Overweight by KeyCorp, with a revised price target of $325.00. McEwen Mining received a Buy rating from Roth MKM, with a target of $15.00. Medical Properties Trust was rated Sector Perform by Royal Bank Of Canada, with a lowered target of $4.50. Medtronic was upgraded to Peer Perform by Wolfe Research. Microsoft was reiterated with a Positive rating by UBS Group. Mister Car Wash was initiated with a Neutral rating by BTIG Research. Moderna received a Hold rating from Morgan Stanley, targeting $31.00. Neogen was rated Buy by Guggenheim, with a revised target of $10.00. New Gold was initiated with a Market Perform rating by Raymond James Financial, targeting $4.00. Norwegian Cruise Line was rated Neutral by UBS Group, with a reduced price target of $23.00. NOV also received a Hold rating from Citi, targeting $13.00. NOV was rated Sell by Wells Fargo, with a target of $10.00. NU received an Overweight rating from JPMorgan Chase & Co., with a raised target of $16.00. Nuvalent was rated Buy by Goldman Sachs, targeting $105.00. Old Dominion Freight Line was rated Buy by Truist Financial, with an updated target of $180.00. Omeros received a Buy rating from D. Boral Capital, targeting $36.00. Omnicell was rated Buy by Wells Fargo, with a target of $37.00. Oracle also received a Buy rating from TD Cowen, targeting $250.00. Oracle received a Buy rating from Deutsche Bank, with a target of $240.00. Oracle was upgraded to Buy by Stifel Nicolaus, with a target raised to $250.00. OS Therapies was rated Buy by D. Boral Capital, with a target of $20.00. Palomar was rated Outperform by Keefe, Bruyette & Woods, with a revised target of $204.00. Par Pacific received an Outperform rating from Raymond James Financial, with a raised price target of $30.00. Parker Hannifin received a Buy rating from BofA Securities, with a target of $715.00. Pegasystems was rated Buy by Loop Capital, with an increased price target of $60.00. Planet Labs PBC was initiated with a Neutral rating by The Goldman Sachs Group, targeting $4.60. PNC Financial received a Buy rating from RBC Capital, aiming for $195.00. Porch Group received a Buy rating from Financial, targeting $15.00. ProKidney was downgraded to Underperform by Bank of America, with a lowered target of $1.00. Protagonist Therapeutics received a Buy rating from Citi, with a price target of $72.00. Qorvo was also rated Hold by Mizuho Securities, targeting $84.00. Regeneron Pharmaceuticals was downgraded to Hold by Argus. Robinhood Markets received a Buy rating from KeyBanc, targeting $110.00. Robinhood Markets was rated Buy by Barclays, targeting $57.00. Roblox received an Overweight rating from JPMorgan Chase & Co., with a raised target of $120.00. Rocket Lab was initiated with a Neutral rating by The Goldman Sachs Group, targeting $27.00. Rocket Pharmaceuticals received a Hold rating from Morgan Stanley, with a target of $7.00. SailPoint was initiated with an Overweight rating by Cantor Fitzgerald, targeting $29.00. Schlumberger received an Overweight rating from JPMorgan Chase & Co., with a lowered target of $44.00. Schlumberger was rated Buy by Wells Fargo, targeting $43.00. SEI Investments was rated Outperform by Oppenheimer, with a raised target of $96.00. SharkNinja, Inc. was rated Buy by Jefferies, with a target of $175.00. Skyworks Solutions received a Hold rating from Mizuho Securities, with a target of $75.00. Smurfit Westrock received an Overweight rating from Barclays, with a slightly lowered target of $63.00. Southern Copper received a Hold rating from UBS, with a price target of $105.00. Starbucks was initiated with an Outperform rating by CICC Research, targeting $100.00. Stevanato Group was reiterated as Outperform by William Blair. Strategy was rated Buy by TD Cowen, targeting $590.00. Summit Therapeutics received a Buy rating from UBS, with a target of $30.00. Synopsys received a Hold rating from Wells Fargo, with a price target of $520.00. TD SYNNEX was rated Buy by Loop Capital, with an increased target of $160.00. Tempus AI was rated Buy by Guggenheim, with a raised target of $75.00. Tesla received a Buy rating from Deutsche Bank, with a price target of $345.00. Tesla was rated Buy by Morgan Stanley, with a price target of $410.00. Tesla was reiterated as Buy by Canaccord Genuity Group, with a target of $303.00. Transdigm Group was rated Buy by BofA Securities, with a price target of $1,615.00. Tronox was downgraded to Underperform by BMO Capital Markets, with a reduced target of $3.00. Tyra Bioscience was rated Buy by Oppenheimer, targeting $30.00. Unifirst received a target price of $197.00 set by Robert W. Baird. Unifirst was rated Underweight by Barclays, with a price target of $152.00. Unifirst was reiterated as Neutral by UBS Group. United Therapeutics was rated Buy by UBS Group, with a lowered target of $385.00. US Bancorp was rated Buy by RBC Capital, with a price target of $50.00. US Gold was assigned a Buy rating by Roth MKM, aiming for $18.00. Valero Energy was rated Strong-Buy by Raymond James Financial, with a raised target of $155.00. Vipshop received an Overweight rating from JPMorgan Chase & Co., with a decreased target of $18.00. Vipshop was given a Hold rating by Citi, with a target of $17.00. Virgin Galactic was initiated with a Neutral rating by The Goldman Sachs Group, targeting $3.00. Vor Biopharma was upgraded to Buy by HC Wainwright, targeting $3.00. Wabash National received a Hold rating from D.A. Davidson, with a target of $9.50. Walt Disney was upgraded to Buy by Jefferies Financial Group, with a target of $144.00. Waystar was initiated with an Outperform rating by Mizuho, targeting $48.00. Whirlpool was upgraded to Buy by Longbow Research, targeting $145.00. Wingstop was rated Buy by BTIG, with a target of $430.00. Winnebago Industries was rated Buy by Benchmark, with a reduced price target of $42.00. XPO was rated Buy by Truist Financial, with a raised target of $135.00. Zai Lab received an Outperform rating from Leerink Partners, with a revised target of $75.00. Zai Lab was assigned a Buy rating by Citi, with a target of $66.00. Zai Lab was rated Buy by Leerink Partners, with a price target of $75.00. Zynex was reiterated as Buy by HC Wainwright, targeting $8.00.
Yahoo
14-05-2025
- Business
- Yahoo
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments supports projected operations into 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. 'We believe that there is a significant, untapped opportunity to target anti-hunger signaling to treat rare metabolic diseases and obesity. Our lead candidate, ARD-101, is intended to address hunger by lowering the discomfort of fasting without notably decreasing the desirability of food or inducing nausea,' said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. 'The Phase 3 HERO study of ARD-101 in PWS shows our commitment to addressing unmet needs in this community.' Summary of Business Highlights In February 2025, Aardvark successfully completed its initial public offering (IPO), raising $97.9 million in gross proceeds. After deducting underwriting discounts, commissions, and offering expenses, the Company received approximately $87.5 million in net proceeds. Aardvark's stock began trading under the symbol 'AARD' on February 13, 2025. Select First Quarter 2025 Financial Highlights Cash Position: As of March 31, 2025, Aardvark had cash, cash equivalents, and short-term investments of $151.3 million, which includes the net proceeds from the IPO in February 2025. Based on current operating plans, Aardvark believes that its existing cash, cash equivalents, and short-term investments, together with the proceeds from the IPO, will be sufficient to fund projected operations into 2027. R&D Expenses: Research and development expenses were $7.8 million and $1.2 million for the quarter ended March 31, 2025 and 2024, respectively. The $6.6 million increase for the quarter ended March 31, 2025, resulted from increased development costs primarily related to ARD-101 and an increase in personnel-related expenses. G&A Expenses: General and administrative expenses were $2.7 million and $0.9 million for the quarter ended March 31, 2025, and 2024, respectively. The $1.9 million increase for the quarter ended March 31, 2025, primarily resulted from increases in professional fees, facilities and other and personnel-related costs, which were partially related to commencing operations as a public company. Net loss: Net loss was $9.3 million and $2.2 million for the quarter ended March 31, 2025, and 2024, respectively. About Aardvark Therapeutics, Inc. Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of PWS and metabolic diseases. Recognizing hunger (the discomfort from not having eaten recently) is a distinct neural signaling pathway separate from appetite (the reward-seeking, desirability of food). Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. ARD-101 is also being studied in hypothalamic obesity. Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions. For more information, visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning: Aardvark's future results of operations and financial position, business strategy, product candidates, ongoing clinical trials, planned clinical trials, expected timing for data readouts and reporting topline results, anticipated cash runway, likelihood of success, as well as plans and objectives of management for future operations. The words, without limitation, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to potential delays in the commencement, enrollment and completion of clinical trials; the risk that we may use our capital resources sooner than expected and that they may be insufficient to allow us to achieve our anticipated milestones; risks related to our dependence on third parties for manufacturing, shipping and clinical and preclinical trials; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; and other factors discussed in the 'Risk Factors' section of Aardvark's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 to be filed with the Securities and Exchange Commission on or about the date hereof. When evaluating Aardvark's business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark's management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contact: Carolyn Hawley, Inizio Evoke Comms (619) 849-5382 Aardvark Therapeutics, Inc. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended March 31, 2025 2024 Operating expenses: Research and development $ 7,755 $ 1,207 General and administrative 2,715 861 Credit loss—related party accounts receivable — 103 Total operating expenses 10,470 2,171 Loss from operations (10,470 ) (2,171 ) Total other income (expense), net 1,160 (7 ) Net loss $ (9,310 ) $ (2,178 ) Net loss per share of common stock, basic and diluted $ (0.71 ) $ (0.55 ) Weighted-average shares used in net loss per share calculation 13,194,718 3,967,333 Aardvark Therapeutics, Inc. Condensed Consolidated Balance Sheets (in thousands, except share amounts) March 31, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 26,504 $ 61,641 Short-term investments 124,756 12,022 Prepaid expenses and other current assets 3,294 474 Total current assets 154,554 74,137 Operating lease right-of-use asset 628 735 Other assets 1,843 2,635 Total assets $ 157,025 $ 77,507 Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) Current liabilities: Accounts payable $ 2,556 $ 2,298 Accrued liabilities 3,030 2,291 Operating lease liability, current portion 390 338 Total current liabilities 5,976 4,927 Operating lease liability, net of current portion 336 441 Other long-term liabilities 24 26 Total liabilities 6,336 5,394 Commitments and contingencies Convertible preferred stock — 126,756 Stockholders' equity (deficit): Common stock — — Additional paid-in-capital 218,282 3,684 Accumulated other comprehensive income 44 — Accumulated deficit (67,637 ) (58,327 ) Total stockholders' equity (deficit ) 150,689 (54,643 ) Total liabilities, convertible preferred stock, and stockholders' equity (deficit) $ 157,025 $ 77,507 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
